2020年ATC肝移植研究前沿盘点

李海波; 汪国营; 蔡建业; 冯啸; 曾凯宁; 杨扬

doi:10.3969/j.issn.1674-7445.2021.01.005

2020年ATC肝移植研究前沿盘点

doi: 10.3969/j.issn.1674-7445.2021.01.005

510630 广州，中山大学附属第三医院肝脏外科暨肝移植中心

基金项目:

国家“十三五”重大科技专项 2017ZX10203205

广东省科技计划项目 2017B020209004

广东省科技计划项目 2019B020236003

详细信息

通讯作者:
杨扬，男，1971年生，博士，主任医师，研究方向为肝移植，Email：yysysu@163.com

中图分类号: R617, R619+.3, R735.7
计量
- 文章访问数: 555
- HTML全文浏览量: 134
- PDF下载量: 67
- 被引次数: 0
出版历程
- 收稿日期: 2020-09-30
- 网络出版日期: 2021-01-19
- 刊出日期: 2021-01-19

Summary of the research frontiers of liver transplantation in 2020 ATC

Department of Hepatic Surgery, Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

More Information

Corresponding author: Yang Yang, Email: yysysu@163.com

摘要

摘要: 美国移植年会（ATC）是器官移植领域极具影响力的学术盛会。本文概述了2020年ATC肝移植领域的热点内容，包括供肝获取和质量评估、供肝保存和缺血-再灌注损伤（IRI）、肝细胞癌及其他肝脏恶性肿瘤肝移植、肝移植术后并发症、肝移植免疫学、围手术期管理和供者来源性感染、儿童肝移植、细胞治疗等多个方向的最新研究进展。
- 美国移植年会（ATC） /
- 肝移植 /
- 供肝获取 /
- 供肝保存 /
- 感染 /
- 肝细胞癌（肝癌）肝移植 /
- 儿童肝移植 /
- 移植免疫
Abstract: The American Transplant Congress (ATC) is an influential academic congress in the field of organ transplantation. In this article, the hotspots of liver transplantation in 2020 ATC were summarized, including the latest research progress in donor liver procurement and quality assessment, donor liver preservation and ischemia-reperfusion injury (IRI), liver transplantation for hepatocellular carcinoma and other hepatic malignancies, complications after liver transplantation, transplantation immunology, perioperative management and donor-derived infection, pediatric liver transplantation and cell therapy, etc.
- American Transplant Congress (ATC) /
- Liver transplantation /
- Donor liver procurement /
- Donor liver preservation /
- Infection /
- Liver transplantation for hepatocellular carcinoma (HCC) /
- Pediatric liver transplantation /
- Transplantation immunology

HTML全文

参考文献(17)

[1]	2020 American Transplant Congress Abstracts[J]. Am J Transplant, 2020, 20 (Suppl 3): 5-1166. DOI: 10.1111/ajt.16169.
[2]	谢良波, 夏秋翔, 曾宪鹏, 等.《移植器官质量与安全指南(第6版)》解读——供者及器官的评估和选择标准[J].器官移植, 2020, 11(4):487-491. DOI: 10.3969/j.issn.1674-7445.2020.04.011. XIE LB, XIA QX, ZENG XP, et al. Interpretation of Guide to the Quality and Safety of Organs for Transplantation (6th edition): evaluation and selection criteria for donors and organs[J]. Organ Transplant, 2020, 11(4):487-491. DOI: 10.3969/j.issn.1674-7445.2020.04.011.
[3]	ITO T, NAINI BV, MARKOVIC D, et al. Ischemia-reperfusion injury and its relationship with early allograft dysfunction in liver transplant patients[J]. Am J Transplant, 2020, DOI: 10.1111/ajt.16219[Epubahead of print].
[4]	DENGU F, ABBAS SH, EBELING G, et al. Normothermic machine perfusion (NMP) of the liver as a platform for therapeutic interventions during ex-vivo liver preservation: a review[J]. J Clin Med, 2020, 9(4):1046. DOI: 10.3390/jcm9041046.
[5]	YOSHIKAWA R, MATSUNO N, MORITO N, et al. Evaluation using an isolated reperfusion model for porcine liver donated after cardiac death preserved with oxygenated hypothermic machine perfusion[J]. Ann Transplant, 2018, 23:822-827. DOI: 10.12659/AOT.910008.
[6]	ISHII D, MATSUNO N, GOCHI M, et al. Applicability of hypothermic oxygenate machine perfusion preservation for split-liver transplantation in a porcine model: an experimental study[J]. Ann Transplant, 2020, 25:e919920. DOI: 10.12659/AOT.919920.
[7]	PARAJULI S, AZIZ F, BLAZEL J, et al. The utility of donor specific antibody monitoring and the role of kidney biopsy in simultaneous liver and kidney recipients with denovo donor specific antibodies[J]. Transplantation, 2020, DOI: 10.1097/TP.0000000000003399[Epubahead of print].
[8]	KOVANDOVA B, SLAVCEV A, HONSOVA E, et al. De novo HLA class Ⅱantibodies are associated with the development of chronic but not acute antibody-mediated rejection after liver transplantation[J]. Transpl Int, 2020, DOI: 10.1111/tri.13763[Epubahead of print].
[9]	LEGAZ I, BOIX F, LÓPEZ M, et al. Influence of preformed antibodies in liver transplantation[J]. J Clin Med, 2020, 9(3):708. DOI: 10.3390/jcm9030708.
[10]	WOZNIAK LJ, VENICK RS. Donor-specific antibodies following liver and intestinal transplantation: clinical significance, pathogenesis and recommendations[J]. Int Rev Immunol, 2019, 38(3):106-117. DOI: 10.1080/ 08830185.2019.1630404.
[11]	CHOI D, LIU M, GUTTIKONDA D, et al. Recipient risk factors for acute cellular rejection after orthotopic liver transplant - a single-center, retrospective study[J]. Transpl Int, 2020, DOI: 10.1111/tri.13756[Epubahead of print].
[12]	ZHOU S, MITSINIKOS T, EMAMAULLEE J, et al. Clinicopathologic characteristics of late acute antibody-mediated rejection in pediatric liver transplantation[J]. Transplantation, 2020, DOI: 10.1097/TP.0000000000003469[Epubahead of print].
[13]	KEENAN BP, FONG L, KELLEY RK. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response[J]. J Immunother Cancer, 2019, 7(1):267. DOI: 10.1186/s40425-019-0749-z.
[14]	SO-ARMAH K, FREIBERG M, CHENG D, et al. Liver fibrosis and accelerated immune dysfunction (immunosenescence) among HIV-infected Russians with heavy alcohol consumption - an observational cross-sectional study[J]. BMC Gastroenterol, 2019, 20(1):1. DOI: 10.1186/s12876-019-1136-4.
[15]	CHOUDHARY NS, SARAF N, SAIGAL S, et al. Revisiting chronic rejection following living donor liver transplantation in the tacrolimus era: a single center experience[J]. Clin Transplant, 2018, 32(2). DOI: 10.1111/ctr.13161.
[16]	JADLOWIEC CC, TANER T. Liver transplantation: current status and challenges[J]. World J Gastroenterol, 2016, 22(18):4438-4445. DOI: 10.3748/wjg.v22.i18.4438.
[17]	MEHTA S, LOCKE JE. Human immunodeficiency virus from life taking to life giving: expanding the donor pool by using HIV-positive donors[J]. Curr Opin Organ Transplant, 2020, 25(6): 626-630. DOI: 10.1097/MOT.0000000000000815.